|
Daily Medical Update
Metabolic Dysfunction Associated Steatohepatitis
Tuesday, May 12, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Alimentary pharmacology & therapeutics (2026) - Network Meta-Analysis
Key Findings
- Across 9 RCTs with 3266 participants, efruxifermin was the only intervention significantly superior to placebo for >=1-stage fibrosis improvement without worsening of MASH.
- For MASH resolution, efruxifermin, semaglutide + cilofexor + firsocostat, and semaglutide improved outcomes vs placebo, with SUCRA rankings of 81.38, 74.07, and 63.88, respectively.
📋 Practice Implication: In compensated MASH cirrhosis, efruxifermin currently has the strongest histology signal and is the most defensible option to prioritize when considering advanced-stage trial enrollment.
|
The Journal of clinical endocrinology and metabolism (2025) - Meta-Analysis
Key Findings
- Across 25 RCTs involving 2600 patients, GLP-1RA therapy reduced liver fat content by 5.21%, with retatrutide showing the largest treatment effect.
- GLP-1RAs significantly improved steatosis, hepatocellular ballooning, lobular inflammation, ALT, AST, GGT, and liver stiffness, while fibrosis improvement remained nonsignificant overall.
📋 Practice Implication: For patients with obesity or diabetes plus MASH, GLP-1-class treatment can be framed as a metabolic therapy that also delivers meaningful hepatic improvement short of consistent fibrosis reversal.
|
Endocrinology, diabetes & metabolism (2026) - Network Meta-Analysis
Key Findings
- Efruxifermin produced larger MRI-PDFF reductions than resmetirom (MD -62.83% vs -37.15%) and significantly lowered AST (MD -14.32, 95% CI -23.92 to -4.72), whereas resmetirom did not significantly lower AST.
- Efruxifermin also reduced triglycerides more than resmetirom (MD -36.95 vs -24.72), and the analysis reported more favorable safety outcomes with efruxifermin.
📋 Practice Implication: When choosing between these newer agents, efruxifermin appears better suited to patients where hepatic fat reduction and aminotransferase improvement are the main near-term priorities.
|
BMC medicine (2025) - Meta-Analysis
Key Findings
- Compared with control, the Mediterranean diet reduced body weight (WMD -2.38 kg), BMI (WMD -0.70 kg/m2), waist circumference (WMD -1.56 cm), and ALT (WMD -3.96 IU/L).
- Aerobic and combined aerobic-resistance exercise reduced body weight (WMD -1.56 kg and -1.90 kg), while resistance exercise lowered ALT by WMD -15.40 IU/L.
📋 Practice Implication: Lifestyle prescriptions in MASH should be specific rather than generic, with Mediterranean-pattern nutrition plus structured aerobic or resistance training used as measurable treatment components.
|
Clinica chimica acta; international journal of clinical chemistry (2025) - Meta-Analysis
Key Findings
- In meta-analysis, FLI improved diagnostic discrimination with an AUC of 0.82 for MASLD, FIB-4 reached 0.82 for stage >=3 fibrosis, and NFS reached 0.80 for stage >=2 fibrosis.
- Cross-sectional validation improved confidence in these markers, with FLI reaching an AUC of 0.92 for MASLD and NFS an AUC of 0.88 for MASH.
📋 Practice Implication: Primary care and endocrinology workflows can use FLI, FIB-4, and NFS as scalable triage tools to decide who needs elastography, hepatology referral, or closer fibrosis surveillance.
|
|
💡
Summary
Recent evidence in MASH continues to center on therapy intensification and better monitoring rather than hard clinical outcomes. GLP-1-based agents and newer liver-directed drugs improve liver fat, histology, and liver enzymes, while Mediterranean diet plus structured exercise and low-cost noninvasive scores such as FLI, FIB-4, and NFS remain practical tools for routine management and risk stratification.
|
|